Lexaria Bioscience engages CRO for 2026 GLP-1-A26-1 study

Lexaria Bioscience (LEXX) announced the engagement of the contract research organization to execute and report on its 2026 animal Study #1 that will evaluate a number of formulation enhancements using both DehydraTECH-semaglutide glucagon-like peptide-1 compositions and DehydraTECH-CBD compositions to explore the potential for additional improved performance as well as stake new intellectual property claims. Contracts with the CRO have been signed, materials sourcing is underway, and Study design is being finalized with the goal of beginning dosing within approximately 60 days. While final design parameters of this Study are ongoing, it is expected to utilize Sprague-Dawley rats with 8 to 11 separate arms evaluating a number of different novel compositions. Blood samples will be taken at multiple timepoints through an 8-24-hour post-dosing period to quantify the pharmacokinetic performance of each composition. In addition, the Study will also measure drug concentrations in the brain since DehydraTECH has, in the past, evidenced apparent superior absorption of active ingredients into brain tissue, an area of intense interest due to the fact that GLP-1 drug performance is increasingly understood to include or even depend upon involvement of brain neurochemistry, thus making brain biodistribution vital. There will be one reference arm using an existing DHT-sema composition and another reference arm using an existing DHT-CBD composition. Lexaria intends to leverage the wealth of study data that we have amassed from previous work by utilizing our proprietary historical data and the reference arms as baseline comparators to the current Study results as we search for areas of superiority. One of the novel objectives of this Study will be to evaluate alternative/additive formulations to SNAC which is currently in use by Novo Nordisk with their oral Rybelsus and Wegovy tablet products. If Lexaria is able to establish novel new formulations with superiority to SNAC, we may be able to register new patents and create valuable new proprietary IP and an industry alternative to SNAC that could be of interest within the keenly competitive GLP-1 sector.